Spring sale — 20% off your first order with code SPRING20 at checkout

For in-vitro research only · Not for human use · 18+

Side-by-side · Australia

BPC-157 vs TB-500

The two most-searched recovery-model peptides in Australia. They are studied for overlapping outcomes but through completely different mechanisms, which is why a lot of published work runs them side by side rather than choosing one.

BPC-157

A 15-amino-acid gastric pentadecapeptide studied in gut, tendon and connective-tissue repair models.

From A$89
TB-500

A synthetic fragment of Thymosin Beta-4 studied for actin regulation, cell migration and angiogenesis models.

From A$95

At a glance

 BPC-157TB-500
ClassPentadecapeptide (BPC-157)Thymosin Beta-4 fragment
Chain length15 amino acids7 amino acids (active fragment)
Studied mechanismAngiogenic and growth-factor pathway signalling in tendon, ligament and gut tissue modelsActin sequestration and cell migration, studied in wound and vascular models
Typical vial5mg lyophilised5mg lyophilised
ReconstitutionBacteriostatic water, 2-8°C after mixingBacteriostatic water, 2-8°C after mixing
Purity standardHPLC ≥99%, lot-matched CoAHPLC ≥99%, lot-matched CoA
Most common research pairingLocalised tissue-repair modelsSystemic cell-migration models

The mechanistic difference in plain terms

BPC-157 is a stable fragment of a protein found in gastric juice. The published literature focuses on angiogenesis, growth-factor receptor expression and tendon-to-bone healing in animal and cell models — largely localised effects.

TB-500 is the active fragment of Thymosin Beta-4, a protein involved in actin binding. Research interest centres on cell migration and new blood-vessel formation, and it is generally described as acting more systemically because of its smaller size and distribution.

Neither compound is a therapeutic good in Australia, and neither has TGA approval. Everything above describes what the literature investigates in vitro and in animal models.

Which one do Australian labs order more?

BPC-157 outsells TB-500 in our own order data by a wide margin, mostly because it appears in more accessible published work and is the cheaper 5mg vial.

A meaningful share of orders take both, since a lot of the recovery-model literature examines them together rather than in isolation.

Both ship from our Australian storage and dispatch facility with the same cold-chain packing, so a combined order arrives in one parcel and only pays shipping once.

Verifying whichever you choose

Every vial of both compounds carries a lot number printed on the label that maps to an HPLC and mass-spec Certificate of Analysis. If the two do not match, do not use the vial — contact us and we replace it.

A genuine CoA names the compound, the lot, the assay method, the purity percentage and the test date. A generic PDF with no lot number is a red flag no matter who the supplier is.

Questions people ask

Is BPC-157 or TB-500 better for research?
Neither is 'better' — they are studied for different mechanisms. BPC-157 dominates localised tendon and gut repair models; TB-500 appears in cell-migration and angiogenesis work. Choose based on the model you are running, not on marketing claims.
Can BPC-157 and TB-500 be used together in a study?
A portion of the published literature examines them in combination because their mechanisms are distinct. We supply both at ≥99% HPLC purity so combined-protocol research uses lot-verified material.
Which is cheaper in Australia?
BPC-157 5mg is generally the lower-priced vial of the two. Current AUD pricing for both is shown live on this page and on each product page.
Do both need bacteriostatic water?
Yes. Both ship lyophilised and are reconstituted with bacteriostatic water, then stored at 2-8°C and protected from light and repeated freeze-thaw cycles.
How fast do they ship within Australia?
Both are held in stock in Australia and dispatched same-day on orders placed before 12pm AEST, cold-chain packed, with free express shipping over A$199.